By: Sam A. Kashani, MD
Interest in psychedelic-assisted therapy (PAT) has accelerated dramatically in recent years, moving from the margins of medicine into the center of psychiatric research. More than 130 psilocybin trials have been registered since 2004, with the majority launched in just the past five years (Norring & Birks, 2024). Although psychedelic medications are not FDA-approved, their potential for treating depression, PTSD, and anxiety has captured the attention of clinicians and researchers alike. Importantly, across all available data reviewed, sleep has never been studied as a primary outcome, yet consistent patterns suggest that sleep may play a meaningful role in how these treatments work, and how people recover.
The Sleep Connection
Across compounds such as psilocybin, MDMA, ketamine, and LSD, sleep often improves as psychiatric symptoms improve, even though sleep is a secondary or exploratory measure in most studies.
- Psilocybin
Secondary analyses from depression trials show that early improvements in sleep predict better antidepressant outcomes (Reid et al., 2024), while worse baseline sleep reduces the likelihood of remission. Sleep architecture findings reveal that psilocybin prolongs REM-onset latency and reduces overall REM duration (Dudysová et al., 2020), changes that closely mirror those seen with SSRIs. This similarity supports the long-standing hypothesis that reduced REM sleep may be part of the therapeutic mechanism, potentially decreasing the consolidation of negatively biased emotional memories and promoting neuroplastic conditions that support recovery. - Ketamine
A rapid-acting antidepressant, ketamine has been shown to improve insomnia symptoms within hours to days, including sleep maintenance difficulty and early morning awakenings (Kopciuch et al., 2023). Additionally, polysomnographic data has shown increases in slow-wave activity in the first 1/3rd of the night, a biomarker of neuroplasticity associated with antidepressant response (Duncan et al., 2013). Notably, a naturalistic study of 132 patients demonstrated that those with more severe baseline insomnia experienced faster and more significant antidepressant responses (Liu et al., 2020), a pattern that stands in contrast to traditional antidepressants. It is worth noting that while most psychedelic compounds remain investigational, esketamine (Spravato), a derivative of ketamine, is FDA-approved for treatment-resistant depression (TRD), highlighting ketamine’s unique status in this space and its relevance to clinical practice. - LSD — Lysergic Acid Diethylamide
Recent trials demonstrate sustained reductions in anxiety after a single therapeutic dose of LSD, with nearly half of participants achieving remission at 12 weeks (JAMA, 2024). In a large Phase 1 microdosing study, participants slept about 24 minutes longer on the night after dosing, when drug levels had already cleared, and this increase occurred in the absence of daytime fatigue/somnolence or nighttime sleep disruption on the days of dosing (Murphy et al., 2024). This “sleep rebound” effect may reflect the brain’s attempt to consolidate and integrate psychedelic-induced cognitive and emotional shifts. Clinically, this suggests that spacing doses (e.g., every three days) may be essential to allow for recovery, neural reorganization, and potentially more enduring therapeutic effects. - MDMA — 3,4 Methylenedioxymethamphetamine
In pooled Phase 2 PTSD trials, participants receiving MDMA experienced significant improvements in sleep quality, sleep onset latency, and daytime functioning, with benefits sustained at 12-month follow-up (Ponte et al., 2021). Although MDMA was also shown to disrupt sleep for several nights immediately after dosing, long-term improvements in sleep track closely with PTSD symptom relief, suggesting that enhanced sleep may support or amplify trauma recovery.
What’s Next?
Despite encouraging patterns linking psychedelic therapy and sleep, no RCT has yet directly examined insomnia as a primary target or outcome. Moreover, most sleep data rely on self-report inventories rather than objective tools such as actigraphy or polysomnography, and additional mechanistic research is needed to clarify causal pathways. For these reasons, psychedelics are not ready for use as treatments for sleep disorders. Nevertheless, across compounds and conditions, sleep consistently emerges as a meaningful secondary outcome that often predicts or enhances therapeutic response. As the field evolves, integrating psychedelic research insights into clinical sleep medicine may open new possibilities for restoring both emotional well-being and sleep health.
References
- Dudysová, D., et al. (2020). Frontiers in Pharmacology.
- Duncan, W. C., et al. (2013). International Journal of Neuropsychopharmacology.
- Kopciuch, R., et al. (2023). Pharmaceuticals.
- Liu, Y., et al. (2020). Journal of Affective Disorders.
- Murphy, K., et al. (2024). Translational Psychiatry.
- Norring, A., & Birks, M. (2024). ClinicalTrials.gov analysis.
- Ponte, D., et al. (2021). Journal of Traumatic Stress.
- Reid, H., et al. (2024). Current Psychiatry Reports.
- JAMA (2024). LSD Phase 2b GAD trial.
- Healthcare Brew (2025). Psychedelic regulatory updates.